Research and Clinical Trials

Title  
G1 Therapeutics G1T28-04: Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients with Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Brief Description  
Assess the safety and tolerability of trilaciclib (G1T28) administered with GC therapy.
Who may be Eligible  
Please contact us for eligibility criteria.
Speciality/Disorder  
Breast
Status  
OPEN
Start Date  
04/11/2017
IRB Number  
00020553
Principal Investigator  
Tan, Antoinette Roslyn
Contact Name  
Caroline Watt

For More Information, Contact  Caroline  , Watt
Phone:  980-442-2017 Fax:    
Email:  Caroline.Watt@carolinashealthcare.org
Address:1021 Morehead Medical Drive Suite 2200 Charlotte, 28204
Close